Sexually Transmitted Infections & Diseases
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Vii. Infection Prevention
VII. INFECTION PREVENTION Prevention of Hospital Acquired Infections What is Infection Prevention? Infection prevention is doing everything possible to prevent the spread of germs which lead to hospital acquired infection. What is a bloodborne pathogen? • Bloodborne pathogens are micro-organisms such as viruses or bacteria that are present in human blood that can cause disease in humans. These pathogens include, but are not limited to: – Hepatitis B (HBV) – Hepatitis C (HCV) – Human immuno-deficiency virus (HIV) – Malaria, syphilis, West Nile virus, Ebola OTHER POTENTIALLY INFECTIOUS MATERIAL (OPIM) • In addition to human blood, bloodborne pathogens can be found in other potentially infectious material such as: – Blood products (plasma/serum) – Saliva – Semen – Vaginal secretions – Skin tissue/cell cultures – Any body fluid that is contaminated with blood • Body fluids that are not usually considered infectious with bloodborne pathogens are: – Vomit – Tears – Sweat – Urine – Feces – Sputum /nasal secretions ALL BODY FLUIDS SHOULD BE REGARDED AS POTENTIALLY INFECTIOUS!!! TRANSMISSION IN THE WORKPLACE Bloodborne pathogens can be transmitted when blood or OPIM is introduced into the blood stream of a person • This can happen through: – Non intact skin (acne, scratches, cuts, bites, blisters, wounds) – Contact with mucus membranes found in the eyes, nose and mouth – Contaminated instruments such as needles and sharps METHODS TO PREVENT BLOODBORNE PATHOGEN EXPOSURE A. Standard Precautions – ALL body fluids should be considered as potentially infectious materials – Use stand precautions EVERY TIME you anticipate contact with blood, body fluids, secretions/excretions, broken skin and mucous membranes – Use appropriate personal protective equipment – Decontaminate spills METHODS TO PREVENT BLOODBORNE PATHOGEN EXPOSURE B. Personal Protective Equipment Include: gloves, gowns, laboratory coats, face shields or masks, eye protection, mouthpieces, resuscitation bags, pocket masks, or other ventilation devices. -
Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus
Proc. Natl. Acad. Sci. USA Vol. 86, pp. 6763-6767, September 1989 Medical Sciences Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus (adenovirus animal model/adenovirus-vectored vacdnes) MICHAEL D. LUBECK*, ALAN R. DAVIS*, MURTY CHENGALVALA*, ROBERT J. NATUK*, JOHN E. MORIN*, KATHERINE MOLNAR-KIMBER*, BRUCE B. MASON*, BHEEM M. BHAT*, SATOSHI MIZUTANI*, PAUL P. HUNG*, AND ROBERT H. PURCELLO *Wyeth-Ayerst Research, Biotechnology and Microbiology Division, P.O. Pox 8299, Philadelphia, PA 19101; and tLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 Contributed by Robert H. Purcell, May 30, 1989 ABSTRACT As a major cause of acute and chronic liver which, because oftheir wide prior usage, are good candidates disease as well as hepatocellular carcinoma, hepatitis B virus as vectors. Other less well-characterized small animal models (HBV) continues to pose significant health problems world- for human adenoviruses have been occasionally reported wide. Recombinant hepatitis B vaccines based on adenovirus (11-13) but are likewise nonpermissive for Ad4 and Ad7 vectors have been developed to address global needs for infections (unpublished data). An early study of animal effective control of hepatitits B infection. Although consider- species including nonhuman primates indicated that human able progress has been made in the construction ofrecombinant adenoviruses do not induce acute respiratory disease in adenoviruses that express large amounts of HBV gene prod- monkeys or chimpanzees following intranasal inoculations ucts, preclinical immunogenicity and efficacy testing of candi- (14). Serological data, however, indicated that such experi- date vaccines has remained difficult due to the lack ofa suitable mental infections occasionally induced anti-adenovirus anti- animal model. -
Trichomoniasis — “Trich” for Short — Is an Infection That Is Most Common in Sexually Active Women Age 16 to 35
FACT SHEET FOR PATIENTS AND FAMILIES Trichomoniasis What is trichomoniasis? Trichomoniasis — “trich” for short — is an infection that is most common in sexually active women age 16 to 35. (Men can have trich, too, but usually have fewer symptoms and often don’t need treatment to clear up the infection.) If you have trich, you need medication to stop your symptoms and prevent spreading the infection to sex partners. This handout gives you basic information on trichomoniasis, how it’s treated, and what you can do to prevent it. What causes it? Trichomoniasis is caused by a parasite, a tiny organism called Trichomonas vaginalis. Trich is passed from one person to another through sexual contact. Trich is one of the most common sexually transmitted infections or diseases (STIs or STDs) among young, sexually active women. Recent studies suggest that more Most common in young women, than 2 million women in the U.S. currently have trichomoniasis is a curable infection. trichomoniasis. Why is it a concern? What are the symptoms? Trich is completely curable, but you shouldn’t ignore A woman with trichomoniasis may have one or it. Trich can cause annoying and painful symptoms more of these common symptoms, which may (see the list at right) and may make it easier to catch come and go: another STI such as HIV, the virus that causes AIDS. • Vaginal discharge. The discharge may be gray, If you’re pregnant, trich brings these additional risks: yellow, or green. It may be thin or foamy and may • Your baby may be born too soon smell bad. -
Trichomoniasis Information Handout for Patients
Ottawa County Department of Public Health Family Planning Program Trichomoniasis Information Handout for Patients Trichomoniasis is a sexually transmitted infection caused by the parasite Trichomonas vaginalis. Causes: Trichomoniasis is found worldwide. In the United States, the highest number of cases are seen in women between age 16 and 35. Trichomonas vaginalis is spread through sexual contact with an infected partner. This includes penis-to-vagina intercourse or vulva-to-vulva contact. The parasite cannot survive in the mouth or rectum. The disease can affect both men and women, but the symptoms differ between the two groups. The infection usually does not cause symptoms in men and goes away on its own in a few weeks. Symptoms in Women: •Discomfort with intercourse •Itching of the inner thighs •Vaginal discharge (thin, greenish-yellow, frothy or foamy) •Vaginal itching •Vulvar itching or swelling of the labia •Vaginal odor (foul or strong smell) Symptoms in Men: •Burning after urination or ejaculation •Itching of urethra •Slight discharge from urethra Occasionally, some men with trichomoniasis may develop prostatitis or epididymitis from the infection. Exams and Tests: In women, a pelvic examination shows red blotches on the vaginal wall or cervix. A wet prep (microscopic examination of discharge) may show signs of inflammation or infection-causing organisms in vaginal fluids. A pap smear may also diagnose the condition. The disease can be hard to diagnose in men. Men are treated if the infection is diagnosed in any of their sexual partners. Men may also be treated if they have ongoing symptoms of urethral burning or itching despite treatment for gonorrhea and chlamydia. -
Hepatitis B Fast Facts Everything You Need to Know in 2 Minutes Or Less!
Hepatitis B Foundation Cause for a Cure www.hepb.org Hepatitis B Fast Facts Everything you need to know in 2 minutes or less! Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV) that attacks liver cells and can lead to liver failure, cirrhosis (scarring) or cancer of the liver. The virus is transmitted through contact with blood and bodily fluids that contain blood. Most people are able to fight off the hepatitis B infection and clear the virus from their blood. This may take up to six months. While the virus is present in their blood, infected people can pass the virus on to others. Approximately 5-10% of adults, 30-50% of children, and 90% of babies will not get rid of the virus and will develop chronic infection. Chronically infected people can pass the virus on to others and are at increased risk for liver problems later in life. The hepatitis B virus is 100 times more infectious than the AIDS virus. Yet, hepatitis B can be pre- vented with a safe and effective vaccine. For the 400 million people worldwide who are chronically infected with hepatitis B, the vaccine is of no use. However, there are promising new treatments for those who live with chronic hepatitis B. In the World: • This year alone, 10 to 30 million people will become infected with the hepatitis B virus (HBV). • The World Health Organization estimates that 400 million people worldwide are already chronically infected with hepatitis B. -
Prevention & Control of Viral Hepatitis Infection
Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action © World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Table of contents Disease burden 02 What is viral hepatitis? 05 Prevention & control: a tailored approach 06 Global Achievements 08 Remaining challenges 10 World Health Assembly: a mandate for comprehensive prevention & control 13 WHO goals and strategy -
Body Fluid Exposure Procedure
Employee Health Services 210 Lincoln Street Worcester, MA 01605 Body Fluid Exposure Procedure Step 1: Treat Exposure Site As soon as possible after exposure, use soap and water to wash areas exposed to potentially infectious fluids Flush exposed mucous membranes with water Flush exposed eyes with 500 ml of water or saline, at least 3-5 minutes Do not apply caustic agents, disinfectants or antibiotics in the wound Step 2: Gather Information and Document Employees need to complete a “First Report of Injury” form, state or clinical, as appropriate. Students need to complete an occurrence form. Using the UMMHC PEEP sheet as a guide, document o The circumstances of the occupational exposure o Evaluation of the employee . Evaluation of exposure site . Evaluation of Hepatitis B, C and HIV status Hepatitis B antibody (HBA) Hepatitis B antigen (HSA) Hepatitis C antibody (HCV) HIV antibody . Baseline lab. At the initial visit, we do not necessarily know the disease status of the source patient. Therefore, the baseline labs take into account only the decision to take or decline PEP. No Post-Exposure Prophylaxis (PEP) [2 gold top tubes] Alt HSA HBA HCV HIV Taking Post-Exposure Prophylaxis 2 gold top and 1 purple top tubes All of the above, PLUS AST Amylase Creatinine Glucose CBC/diff UCG as appropriate o Evaluation of the source patient . When the source of the exposure is known Source chart needs to be reviewed and source consented for HIV, Hepatitis B antigen and antibody, and Hepatitis C. J: Employee Health: Body Fluid Exposure Procedure-Revised 09/29/09 jc 1 On the University campus, notify Pat Pehl, the HIV counselor. -
Persistence of Ebola Virus in Various Body Fluids During Convalescence
Epidemiol. Infect. (2016), 144, 1652–1660. © Cambridge University Press 2016 doi:10.1017/S0950268816000054 Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control A. A. CHUGHTAI*, M. BARNES AND C. R. MACINTYRE School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, Australia Received 19 November 2015; Final revision 22 December 2015; Accepted 6 January 2016; first published online 25 January 2016 SUMMARY The aim of this study was to review the current evidence regarding the persistence of Ebola virus (EBOV) in various body fluids during convalescence and discuss its implication on disease transmission and control. We conducted a systematic review and searched articles from Medline and EMBASE using key words. We included studies that examined the persistence of EBOV in various body fluids during the convalescent phase. Twelve studies examined the persistence of EBOV in body fluids, with around 800 specimens tested in total. Available evidence suggests that EBOV can persist in some body fluids after clinical recovery and clearance of virus from the blood. EBOV has been isolated from semen, aqueous humor, urine and breast milk 82, 63, 26 and 15 days after onset of illness, respectively. Viral RNA has been detectable in semen (day 272), aqueous humor (day 63), sweat (day 40), urine (day 30), vaginal secretions (day 33), conjunctival fluid (day 22), faeces (day 19) and breast milk (day 17). Given high case fatality and uncertainties around the transmission characteristics, patients should be considered potentially infectious for a period of time after immediate clinical recovery. -
Trichomoniasis Trichomoniasis Is the Most Common Curable Sexually Transmitted Disease (STD) in the United States
Neglected Parasitic Infections in the United States Trichomoniasis Trichomoniasis is the most common curable sexually transmitted disease (STD) in the United States. Trichomoniasis is caused by infection with a parasite (Trichomonas vagi- nalis). Women and men who have trichomoniasis are at higher risk for getting or spreading other STDs, including HIV. About 3.7 million people in the United States are infected with this parasite, and most do not have any signs or symptoms. Trichomoniasis is treated with prescription antimicrobial medication (one dose of metronidazole or tinidazole) but it is possible to become infected again. Trichomoniasis is considered a Neglected Parasitic Infection, one of a group of diseases that can result in serious illness among those who are infected, yet the burden and impact remain poorly understood. How People get Trichomoniasis: Trichomoniasis is a sexually transmitted disease (STD); the parasite is passed from an infected person to an uninfected person during sex. Women and men with trichomoniasis may notice redness, soreness, or itching of the genitals, burning with urination, or discharge. Without treatment, infection can last for months or even years. Some people develop symptoms within 5 to 28 days after being infected, but others do not develop symp- toms until much later or not at all. About 70% of infected people never have any signs or symptoms. Even without any Trichomonas symptoms, infected people can pass the infection to others. Risk Factors for Acquiring Trichomoniasis: • Both men and women can get infected. • People with more sexual partners are more likely to become infected. • Older women may be more likely than younger women to be infected. -
Sexually Transmitted Infections
Disease Awareness April, 2014 • Members Sexually Transmitted Infections Many infections are spread during sex. In this newsletter, we will talk about the 4 most common ones. Human papillomavirus (HPV) Protect yourself What it causes • Learn about sexually transmitted infections Most of the time HPV goes away on its own and doesn’t cause any problems. But many low-risk types of HPV can cause genital warts. High-risk types can • Practice safe sex cause cervical cancer. • Get tested Symptoms Genital warts are a sign of infection with a low-risk type of HPV. The warts can • Get vaccinated to protect against sometimes itch, burn, or feel tender. They can cause bleeding after sex or an HPV and hepatitis B abnormal fluid coming from the vagina. Not all people will have symptoms. There are no symptoms of the high-risk type of HPV. But signs of an infection can be seen on a Pap smear. Testing Testing is not needed to diagnose the low-risk type. But doctors might test these people for infection with a high-risk type. This is because people with genital warts are sometimes infected with both low-risk and high-risk types of HPV. Since there are no symptoms of the high-risk type, it’s very important for women to be screened. Doctors use the Pap test for this and an HPV DNA test that can detect high-risk types. Talk with your doctor about testing if you are 21 years old or older. Treatment HPV that causes genital warts cannot be cured. Medication can be used to help the warts go away. -
Hepatitis B? HEPATITIS B Hepatitis B Is a Contagious Liver Disease That Results from Infection with the Hepatitis B Virus
What is Hepatitis B? HEPATITIS B Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop Are you at risk? an “acute” infection, which can range in severity from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Acute Hepatitis B refers to the first 6 months after someone is exposed to the Hepatitis B virus. Some people are able to fight the infection and clear the virus. For others, the infection remains and leads to a “chronic,” or lifelong, illness. Chronic Hepatitis B refers to the illness that occurs when the Hepatitis B virus remains in a person’s body. Over time, the infection can cause serious health problems. How is Hepatitis B spread? Hepatitis B is usually spread when blood, semen, or other body fluids from a person infected with the Hepatitis B virus enter the body of someone who is not infected. This can happen through having sex with an infected partner; sharing needles, syringes, or other injection drug equipment; or from direct contact with the blood or open sores of an infected person. Hepatitis B can also be passed from an infected mother to her baby at birth. Who should be tested for Hepatitis B? Approximately 1.2 million people in the United States and 350 million people worldwide have Hepatitis B. Testing for Hepatitis B is recommended for certain groups of people, including: Most are unaware of their infection. ■ People born in Asia, Africa, and other regions with moderate or high rates Is Hepatitis B common? of Hepatitis B (see map) Yes. -
Genital Herpes
Genital herpes FACT SHEET Summary Published Genital herpes is a sexually transmitted infection caused by the 2016 herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Once a person is infected with HSV, the virus stays in the body for life. Both HSV-1 and HSV-2 can be transmitted through sexual contact. Genital herpes is an HSV infection of the groin, pubic CONTACT US area, genital area, anus, rectum or buttocks. by telephone 1-800-263-1638 All people who are sexually active may be at risk for 416-203-7122 genital herpes. by fax Many people with genital herpes have no symptoms or the 416-203-8284 symptoms are very mild so they go unnoticed or are mistaken for another skin condition. The most common symptoms of by e-mail genital herpes are lesions, which appear as painful blisters in [email protected] the genital area. by mail 555 Richmond Street West To test for genital herpes, samples are taken from the sites of Suite 505, Box 1104 suspected infection and tested for the presence of the virus. Toronto ON M5V 3B1 Blood tests can also be used to determine if HSV-1 or HSV-2 is present in the body. Antiviral medications can reduce the severity and frequency of genital herpes outbreaks. Genital herpes increases the risk of HIV transmission. Correct and consistent condom use and antiviral medication can reduce the risk of genital herpes transmission. Key messages on genital herpes for clients are available at the end of this fact sheet. The words we use here – CATIE is committed to using language that is relevant to everyone.